Liver cancer screening in high-risk populations.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2016-01-01 Epub Date: 2015-11-30 DOI:10.2217/hep.15.35
Morris Sherman
{"title":"Liver cancer screening in high-risk populations.","authors":"Morris Sherman","doi":"10.2217/hep.15.35","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with liver disease have a risk of developing hepatocellular carcinoma (HCC), but the risk varies between different diseases and is also different according to several other variables, such as age, type of underlying liver disease and severity of disease. Several risk scores have been developed to more adequately quantitate HCC risk in individual patients. Each risk score is applicable to a specific population (chronic hepatitis B or C, patients on the transplant list, cirrhosis in general, and so on). Most publications on risk scores do not provide clear guidance as to what level of measured risk is sufficient to trigger surveillance.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 1","pages":"13-18"},"PeriodicalIF":1.2000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep.15.35","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep.15.35","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/11/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Patients with liver disease have a risk of developing hepatocellular carcinoma (HCC), but the risk varies between different diseases and is also different according to several other variables, such as age, type of underlying liver disease and severity of disease. Several risk scores have been developed to more adequately quantitate HCC risk in individual patients. Each risk score is applicable to a specific population (chronic hepatitis B or C, patients on the transplant list, cirrhosis in general, and so on). Most publications on risk scores do not provide clear guidance as to what level of measured risk is sufficient to trigger surveillance.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高危人群的肝癌筛查
肝脏疾病患者有发生肝细胞癌(HCC)的风险,但不同疾病之间的风险不同,并且根据其他几个变量(如年龄、潜在肝脏疾病类型和疾病严重程度)也有所不同。一些风险评分已经被开发出来,以更充分地量化个体患者的HCC风险。每个风险评分适用于特定人群(慢性乙型或丙型肝炎,移植名单上的患者,一般的肝硬化,等等)。大多数关于风险评分的出版物都没有提供明确的指导,说明测量的风险达到何种程度才足以引发监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hepatic Oncology
Hepatic Oncology ONCOLOGY-
CiteScore
0.40
自引率
0.00%
发文量
4
审稿时长
13 weeks
期刊介绍: Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
期刊最新文献
Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada. The predictive value of liver tests for the presence of liver metastases. Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study. Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting. Management of hepatocellular carcinoma from diagnosis in routine clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1